Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

PURPOSE: To determine the effects of bevacizumab on patient-reported outcomes (PROs; secondary end point) in the AURELIA trial. PATIENTS AND METHODS: Patients with platinum-resistant ovarian cancer were randomly assigned to chemotherapy alone (CT) or with bevacizumab (BEV-CT). PROs were assessed usi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Stockler, Martin R., Hilpert, Felix, Friedlander, Michael, King, Madeleine T., Wenzel, Lari, Lee, Chee Khoon, Joly, Florence, de Gregorio, Nikolaus, Arranz, José Angel, Mirza, Mansoor Raza, Sorio, Roberto, Freudensprung, Ulrich, Sneller, Vesna, Hales, Gill, Pujade-Lauraine, Eric
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2014
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876313/
https://ncbi.nlm.nih.gov/pubmed/24687829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.4240
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia